Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 7, 2015, Pages 2004-2012

  Farrukee, Rubaiyea ^a,b   Leang, Sook Kwan ^a   Butler, Jeff ^a   Lee, Raphael T C ^c   Maurer Stroh, Sebastian ^c,d,e   Tilmanis, Danielle ^a   Sullivan, Sheena ^a   Mosse, Jennifer ^b   Barr, Ian G ^a   Hurt, Aeron C ^a,f  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b UNIVERSITY OF BALLARAT   (Australia)

^c BIOINFORMATICS INSTITUTE   (Singapore)

^d MINISTRY OF HEALTH   (Singapore)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Influenza B lineage; Neuraminidase inhibitors; Oseltamivir; Resistance

Indexed keywords

LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; VIRUS SIALIDASE; ZANAMIVIR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL LINEAGE; ENZYME ACTIVITY; GENETIC SUSCEPTIBILITY; IC50; INFLUENZA B; INFLUENZA VIRUS A; INFLUENZA VIRUS B; NONHUMAN; REVERSE GENETICS; VIRUS MUTATION;

EID: 84936951592     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv065     Document Type: Article

References (58)

1. WHO. Influenza (Seasonal) Fact sheet No. 211. http://www.who.int/mediacentre/factsheets/fs211/en/index.html.
2. Paul GlezenW, Schmier JK, Kuehn CM et al. The burden of influenza B: a structured literature review. Am J Public Health 2013; 103: e43-51.
3. Chen R, Holmes EC. The evolutionary dynamics of human influenza B virus. J Mol Evol 2008; 66: 655-63.
4. McCullers JA, Saito T, Iverson AR. Multiple genotypes of influenza B virus circulated between 1979 and 2003. J Virol 2004; 78: 12817-28.
5. Cooper NJ, Sutton AJ, Abrams KR et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326: 1235.
6. Hayden FG, Belshe R, Villanueva C et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189: 440-9.
7. Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can Commun Dis Rep 2001; 27: 37-40.
8. Tashiro M, McKimm-Breschkin JL, Saito T et al. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. Antivir Ther 2009; 14: 751-61.
9. Ikematsu H, Kawai N, Kashiwagi S. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan. J Infect Chemother 2012; 18: 529-33.
10. Kawai N, Ikematsu H, Iwaki N et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006; 43: 439-44.
11. Kawai N, Ikematsu H, Iwaki N et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis 2005; 40: 1309-16.
12. Kawai N, Ikematsu H, Iwaki N et al. Zanamivir treatment is equally effective for both influenza A and influenza B. Clin Infect Dis 2007; 44: 1666.
13. Hatakeyama S, Sugaya N, Ito M et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007; 297: 1435-42.
14. Heinonen S, Silvennoinen H, Lehtinen P et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis 2010; 51: 887-94.
15. Sugaya N, Mitamura K, Yamazaki M et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007; 44: 197-202.
16. Sato M, Saito R, Sato I et al. Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan. Tohoku J Exp Med 2008; 214: 113-20.
17. Singh S, Barghoorn J, Bagdonas A et al. Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis. Clin Drug Investig 2003; 23: 561-9.
18. Sugaya N, Tamura D, Yamazaki M et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 2008; 47: 339-45.
19. Escuret V, Frobert E, Bouscambert-Duchamp M et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J Clin Virol 2008; 41: 25-8.
20. Ferraris O, Kessler N, Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res 2005; 68: 43-8.
21. Hurt AC, Barr IG. Influenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children. Commun Dis Intell Q Rep 2008; 32: 57-62.
22. Hurt AC, Barr IG, Durrant CJ et al. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia. Commun Dis Intell Q Rep 2003; 27: 542-7.
23. McKimm-Breschkin J, Trivedi T, Hampson A et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47: 2264-72.
24. Sheu TG, Deyde VM, Okomo-Adhiambo M et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52: 3284-92.
25. Hurt AC, Ernest J, Deng YM et al. Emergence and spread of oseltamivirresistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009; 83: 90-3.
26. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010; 328: 1272-5.
27. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviralresistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49: 4515-20.
28. Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 2008; 41: 13-9.
29. Gubareva LV, Matrosovich MN, Brenner MK et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178: 1257-62.
30. Gubareva LV, Robinson MJ, Bethell RC et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71: 3385-90.
31. Fujisaki S, Imai M, Takashita E et al. Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs. J Infect Chemother 2013;19: 891-5.
32. Fujisaki S, Takashita E, Yokoyama M et al. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs. Biochem Biophys Res Commun 2012; 429: 51-6.
33. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004; 103: 199-203.
34. Hurt AC, Barr IG, Hartel G et al. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res 2004; 62: 37-45.
35. Ison MG, Gubareva LV, Atmar RL et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193: 760-4.
36. Monto AS, McKimm-Breschkin JL, Macken C et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50: 2395-402.
37. Hatakeyama S, Ozawa M, Kawaoka Y. In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. Clin Microbiol Infect 2010; 17: 1332-5.
38. Jonges M, van der Lubben IM, Dijkstra F et al. Dynamics of antiviralresistant influenza viruses in the Netherlands, 2005-2008. Antiviral Res 2009; 83: 290-7.
39. Okomo-Adhiambo M, Sleeman K, Ballenger K et al. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2010; 2: 2269-89.
40. Wang D, Sleeman K, Huang Wet al. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir. Antiviral Res 2013; 97: 240-4.
41. Barnett JM, Cadman A, Burrell FM et al. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 1999; 265: 286-95.
42. Jackson D, BarclayW, Zürcher T. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 2005; 55: 162-9.
43. Jackson D, Cadman A, Zurcher T et al. A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA. J Virol 2002; 76: 11744-7.
44. Staschke KA, Colacino JM, Baxter AJ et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 1995; 214: 642-6.
45. Cheam AL, Barr IG, Hampson AWet al. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors. Antiviral Res 2004; 63: 177-81.
46. Meetings of the WHO Working Group on Surveillance of Influenza Susceptibility-Geneva November 2011 and June 2012. Weekly Epidemiological Record/Health Section of the Secretariat of the League of Nations, 2012; 87: 369-74.
47. Escuret V, Collins P, Casalegno J et al. A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses. J Infect Dis 2014; 210: 1260-9.
48. Fry AM, Garg S, Gubareva LV et al. Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11. Emerg Infect Dis 2011; 17: 2043-6.
49. Higgins RR, Beniprashad M, Chong-King E et al. Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient. J Clin Microbiol 2012; 50: 2500-2.
50. Okomo-Adhiambo M, Sleeman K, Lysen C et al. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza Other Respir Viruses 2013; 7: 645-58.
51. Carr S, Ilyushina NA, Franks J et al. Oseltamivir-resistant influenza A and B viruses pre-and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J 2011; 30: 284-8.
52. Hoffmann E, Mahmood K, Yang C-F et al. Rescue of influenza B virus from eight plasmids. Proc Natl Acad Sci USA 2002; 99: 11411-6.
53. Killian ML. Hemagglutination assay for the avian influenza virus. Meth Mol Biol 2008; 436: 47-52.
54. Conde P, Guiomar R, Cristóvão P et al. Antiviral resistance: influenza B. 2013. Poster presented at Options for Control of Influenza VIII, South Africa. http://hdl.handle.net/10400.18/1725.
55. Baz M, Abed Y, McDonald J et al. Characterization ofmultidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006; 43: 1555-61.
56. Meijer A, Lackenby A, Hungnes O et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009; 15: 552-60.
57. Burmeister W, Ruigrok R, Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J 1992; 11: 49-56.
58. Laver WG, Bischofberger N, Webster RG. Disarming flu viruses. Sci Am 1999; 280: 78-87.